从进化角度看胰腺癌生物学与遗传学
Pancreatic cancer biology and genetics from an evolutionary perspective.
作者信息
Makohon-Moore Alvin, Iacobuzio-Donahue Christine A
机构信息
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
出版信息
Nat Rev Cancer. 2016 Sep;16(9):553-65. doi: 10.1038/nrc.2016.66. Epub 2016 Jul 22.
Abstract
Cancer is an evolutionary disease, containing the hallmarks of an asexually reproducing unicellular organism subject to evolutionary paradigms. Pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer) is a particularly robust example of this phenomenon. Genomic features indicate that pancreatic cancer cells are selected for fitness advantages when encountering the geographic and resource-depleted constraints of the microenvironment. Phenotypic adaptations to these pressures help disseminated cells to survive in secondary sites, a major clinical problem for patients with this disease. In this Review we gather the wide-ranging aspects of pancreatic cancer research into a single concept rooted in Darwinian evolution, with the goal of identifying novel insights and opportunities for study.
摘要
癌症是一种进化性疾病，具有受进化范式影响的无性繁殖单细胞生物的特征。胰腺导管腺癌（以下简称胰腺癌）就是这一现象的一个特别典型的例子。基因组特征表明，当胰腺癌细胞遇到微环境中地理和资源匮乏的限制时，会因适应性优势而被选择。对这些压力的表型适应有助于扩散的细胞在转移部位存活，这是该疾病患者面临的一个主要临床问题。在本综述中，我们将胰腺癌研究的广泛方面归纳为一个基于达尔文进化论的单一概念，目的是识别新的见解和研究机会。
相似文献
1
Pancreatic cancer biology and genetics from an evolutionary perspective.从进化角度看胰腺癌生物学与遗传学
Nat Rev Cancer. 2016 Sep;16(9):553-65. doi: 10.1038/nrc.2016.66. Epub 2016 Jul 22.
2
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.胰腺癌常见突变基因在肿瘤微环境调节中的作用
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820920969. doi: 10.1177/1533033820920969.
3
Clinical Effect of Driver Mutations of , and in Pancreatic Cancer: A Meta-Analysis.胰腺癌中 、 和 驱动基因突变的临床效应：一项荟萃分析。
Genet Test Mol Biomarkers. 2020 Dec;24(12):777-788. doi: 10.1089/gtmb.2020.0078.
4
Genetics and Biology of Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌的遗传学与生物学
Hematol Oncol Clin North Am. 2015 Aug;29(4):595-608. doi: 10.1016/j.hoc.2015.04.003. Epub 2015 Jun 10.
5
Evolution and dynamics of pancreatic cancer progression.胰腺癌演进与动力学。
Oncogene. 2013 Nov 7;32(45):5253-60. doi: 10.1038/onc.2013.29. Epub 2013 Feb 18.
6
Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.胰腺导管腺癌中 K-ras、p53、c-erbB-2 和 DPC4 的基因改变及其与患者生存的相关性。
Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0.
7
Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.Smad4失活加速Kras（G12D）介导的胰腺肿瘤形成。
Cancer Res. 2007 Sep 1;67(17):8121-30. doi: 10.1158/0008-5472.CAN-06-4167.
8
p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.p16和p53基因改变及积累在胰腺导管内乳头状黏液性肿瘤恶性进展中的作用
J Hepatobiliary Pancreat Surg. 2002;9(1):76-85. doi: 10.1007/s005340200007.
9
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.免疫组化检测到 3 个主要基因（CDKN2A/p16、TP53 和 SMAD4/DPC4）的表达水平强烈预测了可切除胰腺癌患者的生存情况。
Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.
10
Establishment and characterization of 4 new human pancreatic cancer cell lines: evidences of different tumor phenotypes.4种新的人胰腺癌细胞系的建立与鉴定：不同肿瘤表型的证据
Pancreas. 2009 Mar;38(2):184-96. doi: 10.1097/MPA.0b013e31818c746a.
引用本文的文献
1
Polyphenols in Pancreatic Cancer Management: Exploring the Roles and Mechanisms of Resveratrol and Epigallocatechin.胰腺癌治疗中的多酚类物质：探索白藜芦醇和表没食子儿茶素的作用及机制
Oncol Res. 2025 Aug 28;33(9):2243-2262. doi: 10.32604/or.2025.065222. eCollection 2025.
2
Serum Circ-DLGAP4 and miR-9 as Potential Biomarkers in Pancreatic Cancer.血清环状DLGAP4和miR-9作为胰腺癌的潜在生物标志物
J Clin Lab Anal. 2025 Aug;39(16):e70076. doi: 10.1002/jcla.70076. Epub 2025 Jul 25.
3
Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications.胃肠道癌症的免疫疗法：关键试验的经验教训及未来临床应用
Antibodies (Basel). 2025 Jul 11;14(3):58. doi: 10.3390/antib14030058.
4
Comprehensive analysis identifies AMIGO2 as a potential prognosis biomarker of pancreatic adenocarcinoma.综合分析确定AMIGO2为胰腺腺癌的潜在预后生物标志物。
J Gastrointest Oncol. 2025 Jun 30;16(3):1287-1304. doi: 10.21037/jgo-2025-7. Epub 2025 Jun 23.
5
Oncogenic and tumor-suppressive forces converge on a progenitor-orchestrated niche to shape early tumorigenesis.致癌力量和肿瘤抑制力量汇聚于祖细胞精心构建的生态位，以塑造早期肿瘤发生。
bioRxiv. 2025 Jun 12:2025.06.10.656791. doi: 10.1101/2025.06.10.656791.
6
Elevated KRAS protein level is associated with better survival in pancreatic cancer.KRAS蛋白水平升高与胰腺癌患者更好的生存率相关。
BMC Cancer. 2025 Jul 1;25(1):1080. doi: 10.1186/s12885-025-14461-w.
7
Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer.自我扩增的NRF2-EZH2表观遗传环将KRAS启动的祖细胞转化为侵袭性胰腺癌。
Nat Cancer. 2025 Jun 30. doi: 10.1038/s43018-025-01003-3.
8
Decoding the role of cancer stem cells in digestive tract tumors: Mechanisms and therapeutic implications (Review).解读癌症干细胞在消化道肿瘤中的作用：机制与治疗意义（综述）
Int J Oncol. 2025 Jul;67(1). doi: 10.3892/ijo.2025.5767. Epub 2025 Jun 27.
9
Comprehensive analysis of SQOR involvement in ferroptosis resistance of pancreatic ductal adenocarcinoma in hypoxic environments.缺氧环境下SQOR参与胰腺导管腺癌铁死亡抗性的综合分析。
Front Immunol. 2025 May 1;16:1513589. doi: 10.3389/fimmu.2025.1513589. eCollection 2025.
10
Prognostic Impact of Phenotypic and Genetic Features of Pancreatic Malignancies.胰腺恶性肿瘤的表型和基因特征对预后的影响
Life (Basel). 2025 Apr 11;15(4):635. doi: 10.3390/life15040635.
本文引用的文献
1
Current perspectives between metabolic syndrome and cancer.代谢综合征与癌症之间的当前观点。
Oncotarget. 2016 Jun 21;7(25):38959-38972. doi: 10.18632/oncotarget.8341.
2
Genomic analyses identify molecular subtypes of pancreatic cancer.基因组分析确定了胰腺癌的分子亚型。
Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.
3
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.等位基因特异性抑制剂通过捕获机制使突变型KRAS G12C失活。
Science. 2016 Feb 5;351(6273):604-8. doi: 10.1126/science.aad6204. Epub 2016 Jan 14.
4
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
5
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.用靶向非活性状态的小分子选择性抑制致癌性KRAS输出
Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6.
6
Current progress in immunotherapy for pancreatic cancer.胰腺癌免疫治疗的当前进展。
Cancer Lett. 2016 Oct 10;381(1):244-51. doi: 10.1016/j.canlet.2015.12.020. Epub 2015 Dec 23.
7
Substantial contribution of extrinsic risk factors to cancer development.外在风险因素对癌症发展的重大贡献。
Nature. 2016 Jan 7;529(7584):43-7. doi: 10.1038/nature16166. Epub 2015 Dec 16.
8
Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.全基因组测序确定家族性胰腺癌的遗传异质性。
Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.
9
The mathematics of cancer: integrating quantitative models.癌症的数学：整合定量模型。
Nat Rev Cancer. 2015 Dec;15(12):730-45. doi: 10.1038/nrc4029.
10
The Path to Cancer --Three Strikes and You're Out.通向癌症之路——三击出局。
N Engl J Med. 2015 Nov 12;373(20):1895-8. doi: 10.1056/NEJMp1508811.
Zotero 插件